BioHub Maryland’s Post

Are you planning a clinical trial in metabolic disorders? Meet Anshul Sharma in San Francisco in January 2025 for the EBD Biotech Showcase and discuss how our advanced methodologies and recruitment strategies can ensure the success of your trial!

💵Honesty pays off - to the tune of £90 million: https://hubs.ly/Q02ZX6lt0 Dr Robin Carr, CEO of Myricx Bio, highlights how transparency about negative data helped them maintain healthy relationship with investors and secure a £90m Series A funding round—the largest for a European biotech spinout. During the recent Imperial Founders Forum event, he shared how by fostering trusting relationships with investors, the team successfully pivoted from small molecules to innovative antibody-drug conjugates (ADCs), turning challenges into breakthroughs. The event included insights from some of our top academic entrepreneurs Professor Richard Craster | Professor Peter Cawley | Dr Andrew Bell | Dr Roberto Solari | Professor Ed Tate | British Patient Capital | The Francis Crick Institute

"We are committed here to working with academia, industry and scientists all over the globe to transform our approaches to treatment and care of people in the long term." In our final introductory video with Professor Paul M Matthews, hear how the Franklin fits within the biotech landscape.

Early bird rates end June 3 for BioCentury Grand Rounds – an R&D conference in Nashville for academic innovators, researchers, investors and industry leaders to explore the translational science behind the next wave of biotech breakthroughs and the people driving them. Take advantage of these special rates and make connections with peers across the biopharma sphere as we discuss: ➤ What Investors Want: Gain insights from top investors on what they’re looking for in today’s market.   ➤ New Investible Space: Discover emerging sectors and opportunities that are catching the eye of investors.   ➤ Measurements of Translational Success: Learn how to measure and showcase the impact of your innovations. Register now to secure your spot at #BioCenturyGrandRounds: https://loom.ly/yydzbC8 Submit your nominations to join the Presenting Companies Class of 2024 by June 3 to lock in early bird rates: https://loom.ly/GHHuDog #GrandRounds #BiotechBreakthroughs #researchdevelopment #academia #venturecapital #biotech #drugdiscovery #drugdevelopment #RnD

🚀 Biotech professionals, it’s time to level up your conference game in 2025! In the latest episode of #BIOfromtheBAYOU, James Zanewicz, JD, LLM, RTTP, and Elaine H., introduce The BioPlanner—a free resource for navigating biotech events like never before. 💡 What you'll discover: - Effortless ways to filter and find biotech conferences tailored to your goals. - Exclusive features like personalized event tracking and submitting your own events. - A bold vision to connect and grow the biotech community in 2025. 🎧 Tune in now and see how TheBioPlanner.com can transform your business development strategy. 👉 Listen now: https://lnkd.in/gzmN9VWB #Biotech #KeyOpinionLeaders #BiotechConferences #BusinessDevelopment

Discover how Nordicus Partners (OTCQB: NORD) accelerates Nordic life sciences into the US market. In this exclusive interview, CEO Henrik Rouf delves into Nordicus Partners' biotech innovations, highlighting Orocidin and Bio-Convert ApS, which target diseases with significant unmet medical needs. He also reveals the company’s distinctive, debt-free growth strategy driving their success. 💡 Don’t miss it: https://lnkd.in/gkbiq_vE #LifeSciences #Biotech #StocksToBuy #StocksToWatch #StockMarket #GlobalOneMedia

📆 Join Camille Samuels of Venrock, Tim Scott of Biocom California, Nina Kjellson of Canaan Partners and Greg Bisconti of JLL for a life sciences #venturecapital outlook webinar. What are the lessons from 2024 and what's in store for 2025? Regardless of fluctuation, venture and other risk capital investments have fueled #biotech innovation and set the groundwork for life sciences industry growth. Both early stage and mature life sciences companies can benefit from the insights shared. Register now >> #JLLLifeSciences #biotechventurecapital

One company optimizing protein conjugates, one company screening for optimal efficacy and therapeutic window of protein conjugates. Well played, #RESIBoston2024 #ADCs #startup #proteinconjugation

DATA for AI Another super exciting discussion topic during #BioTechX USA  was Inter-Atlantic AI collaboration. As we all know the new EU AI Act puts extensive requirements on how sensitive data may be utilized in training and validation of AI models. This is nicely described e.g. on https://lnkd.in/gqxACUza In BioTechX USA we discussed the topic. It is not only tech giants that are concerned about the privacy risks, but high-compliance pharma companies and CROs obviously want to take it very seriously. A key take-home message is that the most secure possibility to avoid privacy risks in AI training and validation is to make data anonymous BEFORE it is taken into AI use. This is exactly what we are doing in some hospital, pharma and medtech projects. We anonymize data so that it can be used safely in AI purposes. Of course there still remains two questions to be answered. The first  comes from the legal department or compliance officers. They ask if the data truly is anonymous. This is a topic that we have elaborated  e.g. in @Findata projects. In practice we run a rich set of tests to verify that data actually passes given anonymity framework. Moreover, we perform a set of attack models to mimic the behavior of an attacker in order to give additional safeguards. The second question comes from the data end-users, data scientists and regulators. Anonymization and synthetization techniques “touch the data” - i.e. make modifications or maskings to the data. It is a fair question if the data is still representative and of high quality. For that purpose we have developed a data utility framework, where we actually run a rich protocol to make the data transformations and data utility implications both transparent and manageable. (A third interesting question comes from the regulators: as anonymization techniques are (and should be) irreversible. Otherwise they are not anonymization but pseudonymization techniques, which are a much weaker form of privacy protection. However, e.g., in clinical trials there is a strong legacy of requiring full traceability of the data. I will write later about this interesting topic.)

Turning scientific breakthroughs into real-world solutions can be an overwhelming prospect. Discover best practices for forging strategic partnerships and how these could pave the way to biotech success in this webinar, sponsored by Cook MyoSite >>> https://hubs.ly/Q02xfDgb0